# PTPN5

## Overview
PTPN5 is a gene that encodes the striatal-enriched protein tyrosine phosphatase (STEP), a non-receptor type protein tyrosine phosphatase predominantly expressed in the brain. STEP plays a crucial role in neuronal signaling by modulating synaptic plasticity, which is essential for learning and memory processes. The protein functions by dephosphorylating key substrates, including components of glutamate receptors and various kinases, thereby influencing receptor internalization and synaptic signaling pathways. The regulation of STEP activity is complex, involving post-translational modifications and interactions with other proteins, which are critical for maintaining synaptic balance. Dysregulation of STEP has been implicated in several neuropsychiatric and neurological disorders, making it a potential therapeutic target for conditions such as Alzheimer's disease and schizophrenia (GoebelGoody2011Therapeutic; Guerrero2024Pushed; Xu2015Inhibition).

## Structure
The PTPN5 gene encodes the striatal-enriched protein tyrosine phosphatase (STEP), which is a brain-specific enzyme involved in neuronal signaling. STEP contains a catalytic domain typical of protein tyrosine phosphatases (PTPs), characterized by a conserved cysteine residue essential for its enzymatic activity (Guerrero2024Pushed). The protein structure includes several loops, such as the WPD loop, which plays a critical role in catalysis and remains atypically open under certain conditions, potentially influenced by environmental factors or regulator binding (Guerrero2024Pushed).

STEP's structure is sensitive to temperature and pressure, which induce distinct conformational changes. High temperature tends to expand the protein volume and stabilize a more global active-like state, while high pressure causes local changes, particularly in the E loop, which shows dual conformations (Guerrero2024Pushed). These conditions also affect the solvation patterns and the arrangement of sulfate molecules in the active site, highlighting the protein's structural plasticity (Guerrero2024Pushed).

STEP may have multiple isoforms due to alternative splicing, and its activity is regulated by post-translational modifications such as phosphorylation (Guerrero2024Pushed). The protein's unique conformational states and regulatory mechanisms are significant for its role in neuronal development and function.

## Function
PTPN5, also known as protein tyrosine phosphatase non-receptor type 5, encodes the striatal-enriched protein tyrosine phosphatase (STEP), which is primarily expressed in the brain. STEP is involved in the regulation of synaptic plasticity, a critical process for learning and memory. It achieves this by dephosphorylating key substrates, including the GluN2B subunit of the NMDA receptor and the GluA2 subunit of the AMPA receptor, leading to the internalization of these glutamate receptors and opposing synaptic strengthening (Pelov2012Involvement; Xu2015Inhibition). STEP also dephosphorylates kinases such as ERK1/2 and Fyn, which are involved in synaptic signaling pathways (Zhang2010Genetic; Pelov2012Involvement).

In healthy cells, STEP is localized to post-synaptic compartments and the endoplasmic reticulum, where it modulates the phosphorylation state of its substrates, affecting receptor localization and kinase activity (Xu2015Inhibition). This regulation is crucial for maintaining the balance between synaptic strengthening and weakening, which is essential for normal cognitive functioning. The activity of STEP is counterbalanced by brain-derived neurotrophic factor (BDNF), which promotes synaptic strengthening, highlighting the importance of STEP in cognitive processes (Xu2015Inhibition).

## Clinical Significance
Mutations and alterations in the PTPN5 gene, which encodes the striatal-enriched protein tyrosine phosphatase (STEP), have been implicated in several neuropsychiatric and neurological disorders. Dysregulation of STEP is associated with Alzheimer's disease, schizophrenia, fragile X syndrome, Huntington's disease, and stress-related psychiatric disorders (Hendriks2023Hereditable; GoebelGoody2011Therapeutic). In Alzheimer's disease, elevated STEP levels are observed in the prefrontal cortex, and reducing STEP levels in mice has been shown to improve cognitive performance (Hendriks2013Protein). 

In schizophrenia, variations in the PTPN5 gene have been linked to the disorder and cognitive performance, particularly in specific populations (Hendriks2013Protein; Pelov2012Involvement). The gene's involvement in synaptic plasticity and receptor trafficking is consistent with the glutamate hypothesis of schizophrenia (Pelov2012Involvement). 

A rare missense variant in PTPN5, rs56234898, has been associated with decreased severity of hypertrophic scarring following deep burns, suggesting a potential role in wound healing (Hendriks2023Hereditable; Sood2016Missense). These findings highlight the clinical significance of PTPN5 gene mutations and expression alterations in various conditions.

## Interactions
PTPN5, also known as STEP (striatal-enriched protein tyrosine phosphatase), is involved in several key interactions with proteins that regulate synaptic function and plasticity. STEP dephosphorylates the NR2B subunit of the NMDA receptor (NMDAR), leading to the internalization of NR1/NR2B receptor complexes, which reduces NMDAR activity and opposes long-term potentiation (LTP) (Zhang2010Genetic; Kurup2010AβMediated). This interaction is crucial in the context of Alzheimer's disease, where elevated STEP levels contribute to synaptic dysfunction (Kurup2010AβMediated).

STEP also interacts with the GluR2 subunit of the AMPA receptor (AMPAR), promoting the internalization of GluR1/GluR2 receptor complexes (Pelov2012Involvement). Additionally, STEP dephosphorylates several kinases, including ERK1/2 and Fyn, which are involved in synaptic strengthening and memory consolidation (Zhang2010Genetic; Pelov2012Involvement). These interactions suggest that STEP plays a role in modulating synaptic signaling pathways, impacting cognitive functions.

The regulation of these interactions is complex, involving mechanisms such as ubiquitination and proteasome-mediated degradation, which are influenced by factors like amyloid beta (Aβ) in Alzheimer's disease (Kurup2010AβMediated). These interactions highlight the potential of STEP as a therapeutic target in neurodegenerative and neuropsychiatric disorders.


## References


[1. (Hendriks2013Protein) Wiljan J.A.J. Hendriks and Rafael Pulido. Protein tyrosine phosphatase variants in human hereditary disorders and disease susceptibilities. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1832(10):1673–1696, October 2013. URL: http://dx.doi.org/10.1016/j.bbadis.2013.05.022, doi:10.1016/j.bbadis.2013.05.022. This article has 85 citations.](https://doi.org/10.1016/j.bbadis.2013.05.022)

[2. (Kurup2010AβMediated) Pradeep Kurup, Yongfang Zhang, Jian Xu, Deepa V. Venkitaramani, Vahram Haroutunian, Paul Greengard, Angus C. Nairn, and Paul J. Lombroso. Aβ-mediated nmda receptor endocytosis in alzheimer’s disease involves ubiquitination of the tyrosine phosphatase step61. The Journal of Neuroscience, 30(17):5948–5957, April 2010. URL: http://dx.doi.org/10.1523/jneurosci.0157-10.2010, doi:10.1523/jneurosci.0157-10.2010. This article has 166 citations.](https://doi.org/10.1523/jneurosci.0157-10.2010)

[3. (Hendriks2023Hereditable) Wiljan J. A. J. Hendriks, Remco T. P. van Cruchten, and Rafael Pulido. Hereditable variants of classical protein tyrosine phosphatase genes: will they prove innocent or guilty? Frontiers in Cell and Developmental Biology, January 2023. URL: http://dx.doi.org/10.3389/fcell.2022.1051311, doi:10.3389/fcell.2022.1051311. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fcell.2022.1051311)

[4. (GoebelGoody2011Therapeutic) Susan M. Goebel-Goody, Matthew Baum, Constantinos D. Paspalas, Stephanie M. Fernandez, Niki C. Carty, Pradeep Kurup, and Paul J. Lombroso. Therapeutic implications for striatal-enriched protein tyrosine phosphatase (step) in neuropsychiatric disorders. Pharmacological Reviews, 64(1):65–87, November 2011. URL: http://dx.doi.org/10.1124/pr.110.003053, doi:10.1124/pr.110.003053. This article has 132 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1124/pr.110.003053)

[5. (Sood2016Missense) Ravi F. Sood, Saman Arbabi, Shari Honari, and Nicole S. Gibran. Missense variant in mapk inactivator ptpn5 is associated with decreased severity of post-burn hypertrophic scarring. PLOS ONE, 11(2):e0149206, February 2016. URL: http://dx.doi.org/10.1371/journal.pone.0149206, doi:10.1371/journal.pone.0149206. This article has 13 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0149206)

[6. (Pelov2012Involvement) Ilana Pelov, Omri Teltsh, Lior Greenbaum, Amihai Rigbi, Kyra Kanyas-Sarner, Bernard Lerer, Paul Lombroso, and Yoav Kohn. Involvement of ptpn5, the gene encoding the striatal-enriched protein tyrosine phosphatase, in schizophrenia and cognition. Psychiatric Genetics, 22(4):168–176, August 2012. URL: http://dx.doi.org/10.1097/ypg.0b013e3283518586, doi:10.1097/ypg.0b013e3283518586. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.1097/ypg.0b013e3283518586)

[7. (Xu2015Inhibition) Jian Xu, Pradeep Kurup, Tyler D. Baguley, Ethan Foscue, Jonathan A. Ellman, Angus C. Nairn, and Paul J. Lombroso. Inhibition of the tyrosine phosphatase step61 restores bdnf expression and reverses motor and cognitive deficits in phencyclidine-treated mice. Cellular and Molecular Life Sciences, 73(7):1503–1514, October 2015. URL: http://dx.doi.org/10.1007/s00018-015-2057-1, doi:10.1007/s00018-015-2057-1. This article has 24 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1007/s00018-015-2057-1)

[8. (Zhang2010Genetic) Yongfang Zhang, Pradeep Kurup, Jian Xu, Nikisha Carty, Stephanie M. Fernandez, Haakon B. Nygaard, Christopher Pittenger, Paul Greengard, Stephen M. Strittmatter, Angus C. Nairn, and Paul J. Lombroso. Genetic reduction of striatal-enriched tyrosine phosphatase (step) reverses cognitive and cellular deficits in an alzheimer’s disease mouse model. Proceedings of the National Academy of Sciences, 107(44):19014–19019, October 2010. URL: http://dx.doi.org/10.1073/pnas.1013543107, doi:10.1073/pnas.1013543107. This article has 157 citations.](https://doi.org/10.1073/pnas.1013543107)

[9. (Guerrero2024Pushed) Liliana Guerrero, Ali Ebrahim, Blake T. Riley, Minyoung Kim, Qingqiu Huang, Aaron D. Finke, and Daniel A. Keedy. Pushed to extremes: distinct effects of high temperature versus pressure on the structure of step. Communications Biology, January 2024. URL: http://dx.doi.org/10.1038/s42003-023-05609-0, doi:10.1038/s42003-023-05609-0. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s42003-023-05609-0)